245 related articles for article (PubMed ID: 32820331)
1. Affinity maturation is required for pathogenic monovalent IgG4 autoantibody development in myasthenia gravis.
Fichtner ML; Vieni C; Redler RL; Kolich L; Jiang R; Takata K; Stathopoulos P; Suarez PA; Nowak RJ; Burden SJ; Ekiert DC; O'Connor KC
J Exp Med; 2020 Dec; 217(12):. PubMed ID: 32820331
[TBL] [Abstract][Full Text] [Related]
2. IgG4 autoantibodies against muscle-specific kinase undergo Fab-arm exchange in myasthenia gravis patients.
Koneczny I; Stevens JA; De Rosa A; Huda S; Huijbers MG; Saxena A; Maestri M; Lazaridis K; Zisimopoulou P; Tzartos S; Verschuuren J; van der Maarel SM; van Damme P; De Baets MH; Molenaar PC; Vincent A; Ricciardi R; Martinez-Martinez P; Losen M
J Autoimmun; 2017 Feb; 77():104-115. PubMed ID: 27965060
[TBL] [Abstract][Full Text] [Related]
3. IgG4-mediated autoimmune diseases: a niche of antibody-mediated disorders.
Huijbers MG; Plomp JJ; van der Maarel SM; Verschuuren JJ
Ann N Y Acad Sci; 2018 Feb; 1413(1):92-103. PubMed ID: 29377160
[TBL] [Abstract][Full Text] [Related]
4. Functional monovalency amplifies the pathogenicity of anti-MuSK IgG4 in myasthenia gravis.
Vergoossen DLE; Plomp JJ; Gstöttner C; Fillié-Grijpma YE; Augustinus R; Verpalen R; Wuhrer M; Parren PWHI; Dominguez-Vega E; van der Maarel SM; Verschuuren JJ; Huijbers MG
Proc Natl Acad Sci U S A; 2021 Mar; 118(13):. PubMed ID: 33753489
[TBL] [Abstract][Full Text] [Related]
5. MuSK myasthenia gravis monoclonal antibodies: Valency dictates pathogenicity.
Huijbers MG; Vergoossen DL; Fillié-Grijpma YE; van Es IE; Koning MT; Slot LM; Veelken H; Plomp JJ; van der Maarel SM; Verschuuren JJ
Neurol Neuroimmunol Neuroinflamm; 2019 May; 6(3):e547. PubMed ID: 30882021
[TBL] [Abstract][Full Text] [Related]
6. Passive transfer models of myasthenia gravis with muscle-specific kinase antibodies.
Verschuuren JJGM; Plomp JJ; Burden SJ; Zhang W; Fillié-Grijpma YE; Stienstra-van Es IE; Niks EH; Losen M; van der Maarel SM; Huijbers MG
Ann N Y Acad Sci; 2018 Feb; 1413(1):111-118. PubMed ID: 29356029
[TBL] [Abstract][Full Text] [Related]
7. Characterization of pathogenic monoclonal autoantibodies derived from muscle-specific kinase myasthenia gravis patients.
Takata K; Stathopoulos P; Cao M; Mané-Damas M; Fichtner ML; Benotti ES; Jacobson L; Waters P; Irani SR; Martinez-Martinez P; Beeson D; Losen M; Vincent A; Nowak RJ; O'Connor KC
JCI Insight; 2019 Jun; 4(12):. PubMed ID: 31217355
[TBL] [Abstract][Full Text] [Related]
8. Relation of HLA-DRB1 to IgG4 autoantibody and cytokine production in muscle-specific tyrosine kinase myasthenia gravis (MuSK-MG).
Çebi M; Durmuş H; Yılmaz V; Yentür SP; Aysal F; Oflazer P; Parman Y; Deymeer F; Saruhan-Direskeneli G
Clin Exp Immunol; 2019 Aug; 197(2):214-221. PubMed ID: 30929252
[TBL] [Abstract][Full Text] [Related]
9. Autoimmune Pathology in Myasthenia Gravis Disease Subtypes Is Governed by Divergent Mechanisms of Immunopathology.
Fichtner ML; Jiang R; Bourke A; Nowak RJ; O'Connor KC
Front Immunol; 2020; 11():776. PubMed ID: 32547535
[TBL] [Abstract][Full Text] [Related]
10. Pathogenic IgG4 subclass autoantibodies in MuSK myasthenia gravis.
Plomp JJ; Huijbers MG; van der Maarel SM; Verschuuren JJ
Ann N Y Acad Sci; 2012 Dec; 1275():114-22. PubMed ID: 23278586
[TBL] [Abstract][Full Text] [Related]
11. MuSK IgG4 autoantibodies cause myasthenia gravis by inhibiting binding between MuSK and Lrp4.
Huijbers MG; Zhang W; Klooster R; Niks EH; Friese MB; Straasheijm KR; Thijssen PE; Vrolijk H; Plomp JJ; Vogels P; Losen M; Van der Maarel SM; Burden SJ; Verschuuren JJ
Proc Natl Acad Sci U S A; 2013 Dec; 110(51):20783-8. PubMed ID: 24297891
[TBL] [Abstract][Full Text] [Related]
12. Antibody effector mechanisms in myasthenia gravis-pathogenesis at the neuromuscular junction.
Gomez AM; Van Den Broeck J; Vrolix K; Janssen SP; Lemmens MA; Van Der Esch E; Duimel H; Frederik P; Molenaar PC; Martínez-Martínez P; De Baets MH; Losen M
Autoimmunity; 2010 Aug; 43(5-6):353-70. PubMed ID: 20380584
[TBL] [Abstract][Full Text] [Related]
13. MuSK antibodies, lessons learned from poly- and monoclonality.
Vergoossen DLE; Augustinus R; Huijbers MG
J Autoimmun; 2020 Aug; 112():102488. PubMed ID: 32505442
[TBL] [Abstract][Full Text] [Related]
14. Muscle-Specific Tyrosine Kinase and Myasthenia Gravis Owing to Other Antibodies.
Rivner MH; Pasnoor M; Dimachkie MM; Barohn RJ; Mei L
Neurol Clin; 2018 May; 36(2):293-310. PubMed ID: 29655451
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms associated with the pathogenicity of antibodies against muscle-specific kinase in myasthenia gravis.
Mori S; Shigemoto K
Autoimmun Rev; 2013 Jul; 12(9):912-7. PubMed ID: 23537506
[TBL] [Abstract][Full Text] [Related]
16. A retrospective multicenter study on clinical and serological parameters in patients with MuSK myasthenia gravis with and without general immunosuppression.
Koneczny I; Mané-Damas M; Zong S; De Haas S; Huda S; van Kruining D; Damoiseaux J; De Rosa A; Maestri M; Guida M; Molenaar P; Van Damme P; Fichtenbaum A; Perkmann T; De Baets M; Lazaridis K; Zouvelou V; Tzartos S; Ricciardi R; Losen M; Martinez-Martinez P
Front Immunol; 2024; 15():1325171. PubMed ID: 38715598
[TBL] [Abstract][Full Text] [Related]
17. Long-Lasting Rituximab-Induced Reduction of Specific-But Not Total-IgG4 in MuSK-Positive Myasthenia Gravis.
Marino M; Basile U; Spagni G; Napodano C; Iorio R; Gulli F; Todi L; Provenzano C; Bartoccioni E; Evoli A
Front Immunol; 2020; 11():613. PubMed ID: 32431692
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms underlying B cell immune dysregulation and autoantibody production in MuSK myasthenia gravis.
Stathopoulos P; Kumar A; Heiden JAV; Pascual-Goñi E; Nowak RJ; O'Connor KC
Ann N Y Acad Sci; 2018 Jan; 1412(1):154-165. PubMed ID: 29381221
[TBL] [Abstract][Full Text] [Related]
19. Divalent and monovalent autoantibodies cause dysfunction of MuSK by distinct mechanisms in a rabbit model of myasthenia gravis.
Mori S; Yamada S; Kubo S; Chen J; Matsuda S; Shudou M; Maruyama N; Shigemoto K
J Neuroimmunol; 2012 Mar; 244(1-2):1-7. PubMed ID: 22222307
[TBL] [Abstract][Full Text] [Related]
20. Autoantibody-producing plasmablasts after B cell depletion identified in muscle-specific kinase myasthenia gravis.
Stathopoulos P; Kumar A; Nowak RJ; O'Connor KC
JCI Insight; 2017 Sep; 2(17):. PubMed ID: 28878127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
